Atropos Health vs Triomics (2026)
Both serve the oncology tumour board and they answer different questions. Triomics reads the institution's own charts, oncology tuned, tracing every conclusion back to the pathology and biomarker behind it, with peer reviewed validation and the deepest workflow integration in the trials category. Atropos answers the question that arises after the chart has been read and the literature is silent: what happened to patients like this one, generated as a publication grade observational study across a federated network of de identified records linked only at query time. A cancer centre plausibly needs both, and the sequence is obvious once stated. Read the patient, search the literature, and when the literature has nothing, generate the evidence. What Atropos should be pressed on is the method behind each generated study, because speed does not remove confounding.
- It generates evidence that does not exist yet, running an observational study across a federated network of de identified records when no published trial covers the question.
- Records are linked only at query time rather than pooled, which removes the aggregation risk instead of governing it.
- The output is a study with an inspectable method, so a tumour board can argue with it rather than take it on trust.
- It reads the institution's own oncology charts with a specialty tuned platform, tracing every conclusion back to the pathology and biomarker that produced it.
- Peer reviewed validation in a recognised digital medicine journal is the strongest evidence position in the trials category.
- The output lands where the oncology team already works rather than in a separate research tool.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Atropos Health and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Atropos Health | Triomics |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Trials AI |
| Founded | 2020 | 2021 |
| Headquarters | Palo Alto, California | San Francisco, California |
| Website | atroposhealth.com | triomics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Atropos Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Triomics, Atropos Health grades higher on Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Triomics its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Atropos Health, Triomics grades higher on HIPAA and BAA Posture, FDA and Regulatory Status and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Atropos Health or Triomics?
On the axes where the AI Health Index separates them, Atropos Health grades higher on Model Supply Chain Disclosure and AI Safety and PHI Stewardship, and Triomics grades higher on HIPAA and BAA Posture, FDA and Regulatory Status and EHR and Interoperability Depth. Triomics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Atropos Health and Triomics differ most?
The widest separation the AI Health Index records between Atropos Health and Triomics is on Model Supply Chain Disclosure, where Atropos Health grades A and Triomics grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Atropos Health and Triomics grade the same?
The AI Health Index grades Atropos Health and Triomics the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These answer different questions for the same tumour board, one about this patient's record and one about patients like this patient, so they are sequential rather than alternative. Observational evidence generated on demand carries confounding and selection risks that speed does not remove, so the method of each generated study is what should be reviewed rather than the turnaround time. Atropos publishes no pricing, security attestation or trust centre. Triomics publishes no attestation either. Neither publishes a false negative rate for the patients its search does not surface.